Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 3 3Phase 1/2 2

Status

Recruiting 3

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 7Genitourinary 3Plasma cell 1CNS 1

Conditions

Prostatic Neoplasms 3

Interventions

Docetaxel 77Radiotherapy 73Prednisone 65Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 41Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 30Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Triptorelin Pamoate 23Sunitinib 23Nivolumab 23Radiation 22apalutamide 21Doxorubicin 20darolutamide 18Gonadotropin-Releasing Hormone 18cabozantinib 16abiraterone 16Specimen Handling 16Radiosurgery 16Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × prednylidene × Genitourinary × Clear all
NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Emory University

Phase 3 Recruiting
72 enrolled
Genitourinary

Prostatic Neoplasms

NCT06470243 2026-01-22

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

SWOG Cancer Research Network

Phase 3 Recruiting
528 enrolled
Genitourinary

Prostatic Neoplasms

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

SWOG Cancer Research Network

Phase 3 Recruiting
1,273 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡